COVID-19 antibody library announced

Global peptide, protein and antibody producer ProteoGenix has announced a Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.

The library, created using blood samples from dozens of recovered COVID-19 patients, is adapted for screening with phage display and strives to meet the rising demands for effective antibodies for a broad range of applications.

“Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics and prophylactics to fight against COVID-19,” ProteoGenix co-founder and President Philippe Funfrock said.

“The new Human Immune COVID-19 antibody library developed by ProteoGenix represents an exciting opportunity to solve the current pandemic.”

The diverse library of 1.2 x 10¹⁰ different clones is allied to the fast turnaround time and sensitivity of the screening technology, which is intended to fast-track the discovery of antibodies with the strongest affinity, specificity and viral blocking activity.

“Compared to the hybridoma technology, phage display saves time by allowing us to directly screen highly diverse and human antibody libraries,” ProteoGenix co-founder and CSO Raphaël Hopfner said.

“In addition, when developing therapeutic antibodies, this technique also helps us reduce the time to market by avoiding complex antibody humanisation processes.”

To further fast-track the discovery process, ProteoGenix offers a broad range of ready-made SARS-CoV-2 antigens, as well as fast custom antigen development services for proteins, peptides and small molecules.

Clients can receive 3–10 royalty-free antibody sequences with an optimal affinity within eight weeks or less. Reported to be the first to propose this service, ProteoGenix aims to support the outstanding efforts of teams fighting the COVID-19 pandemic around the world.

Image credit: ©stock.adobe.com/au/chamsitr